NPAT up 287% on $132m non-cash gain as EBITDAFI fell 32%

Stripping that out, operating performance went backwards: revenue fell 4.0% to $126.2m and EBITDAFI fell 31.6% to $60.3m. The NPAT margin of 86.2% is unprecedented in Annolyse's historical baseline (mean 25.0%, range 1.7%–37.5%) and reflects the revaluation gain rather than operating leverage.

Capex rose 63.3% to $124.4m — capex intensity of 98.6% of revenue — while operating cash flow held roughly flat at $29.6m. Pre-lease free cash flow was -$94.8m. Net debt/EBITDA finished at 23.5x, which the historical baseline classifies as unprecedented high (range 4.96x–15.81x, mean 8.5x). No interim dividend was declared, consistent with HY21.

PBT grew 236.8% even though EBITDAFI fell 31.6%, because the gap is bridged by a $132m non-cash investment in associate revaluation flagged in management's release. The cleaner read on operations is the EBITDAFI decline, which sits well below the prior comparable on a revenue base that was already pandemic-depressed. The 86.2% NPAT margin is unprecedented in the historical baseline (mean 25.0%) but is an accounting artefact of revaluation over a small revenue line, not a margin signal.

Leverage is at an unprecedented level into a rising capex cycle. Net debt/EBITDA of 23.5x sits well above the prior 15.7x and the historical range up to 15.8x. The ratio is high partly because EBITDA is depressed, but capex of $124.4m is now nearly equal to revenue and is rising sharply (63.3%). Cash on hand collapsed from $682.4m to $35.1m as the prior equity raise was deployed and borrowings were trimmed from $2.1b to $1.5b.

Working-capital release flattered cash, but trade receivables remain elevated. Operating working capital moved by -$20.8m versus a historical pattern of $16.3m builds — an unprecedented release — driven by trade debtors falling from $46.2m to $25.4m. Debtor days improved to 36.6 from 64.0 but remain above the historical mean of 25.2 days, indicating the release reflects normalisation off a stretched base rather than a structural step down.

The HY21 baseline is not a clean comparator: in FY21, the first half captured only 12.4% of full-year EBITDA and 6.1% of NPAT, so this is a second-half-weighted business whose shape has been further disrupted by border settings. Annualising HY22 revenue gives $252.4m — below FY21's $281.1m — but the second-half trajectory depends on travel reopening that is not addressed by this filing.

What the release does support is a directional read: underlying operations were still contracting at HY22 and the cash and leverage position has tightened materially since HY21. What it does not support is any inference about the full-year recovery profile.

The $132m non-cash investment revaluation is the single largest contributor to NPAT and is flagged by management as such; underlying operating profitability (EBITDAFI) fell 31.6%. The effective tax rate at 16.6% is below the historical mean and below a normalised rate, reflecting the tax treatment of revaluation gains rather than operating tax leverage.

Cash quality is mixed. OCF/EBITDA of 49.1% sits within the historical range (mean 76.7%), and the unprecedented working-capital release of $20.8m — driven by a fall in trade debtors — propped up operating cash flow against a much lower EBITDAFI. Because that release is a one-off normalisation rather than a recurring source, it should not be extrapolated. With capex of $124.4m well above OCF, the period was funded by drawing down the cash buffer.

This briefing cannot assess the travel-volume and pricing trajectory for the second half, which will determine whether the leverage and capex picture normalises or tightens further.